Enovis (ENOV): The Discount Is Real. The Lima Debt Overhang Is the Reason.

Reaffirmed guidance is not raised guidance. That distinction matters when you're trying to decide whether a stock trading at less than one times sales has an unjustified discount or a perfectly rational one.

Enovis reported second-quarter 2026 results on August 6 and left the full-year outlook unchanged. Revenue grew 4.8% organically, adjusted EBITDA margin expanded to 17.9% from 16.2%, and adjusted EPS reached $0.90, up from $0.72. The company reaffirmed its 2026 guidance of $2.31–$2.37 billion in revenue (4–6% organic growth), $425–$435 million in adjusted EBITDA, $3.52–$3.73 in adjusted EPS, and free cash flow conversion of 25% or higher.

The headline question is whether the stock is undervalued at $26.61, with a market cap of $1.54 billion and an enterprise value of $2.81 billion. To answer it, you need the sector comparison first. Valuation without a peer set is just a number.

The Factor Stack

Valuation: C+. ENOV trades at 0.67 times trailing sales and 1.04 times book value. On a quick look that screams cheap. But the GAAP trailing P/E is negative (–1.39x), and the forward P/E is also negative (–8.28x). You can't score a company on earnings multiples when GAAP earnings are in the hole. The enterprise value to sales multiple of 1.22x tells a truer story once you factor in the debt load — and that number is not dramatically cheap for a medtech company. Compare with Zimmer Biomet at 2.16x sales (with positive earnings and an 11.0x EV/EBITDA) and Stryker at 3.83x sales (28.8x P/E, 16.3x EV/EBITDA). ENOV is priced lower, but the earnings gap is not a rounding error — it's structural.

Growth: B–. Revenue grew 4.9% year over year, and Q2 organic growth was 4.8%, with Reconstructive leading at 6% growth and Prevention & Recovery contributing 3.5% organic. Gross profit grew 11.3% year over year, outpacing top-line growth, which signals real margin improvement. That said, 4.8% organic growth is solid but not exceptional in a medtech sector where EY projects 6–7% industry growth for 2025. The company is keeping pace, not outperforming. And Q2 revenue declined 1.1% quarter over quarter, which is not a pattern you want to lean on.

Profitability: D. This is where the discount earns its keep. GAAP operating margin is –47%. GAAP EBITDA margin is –34%. Return on invested capital is –31.7%. Return on equity is –54.3%. The adjusted numbers look much better — 17.9% adjusted EBITDA margin, 61.7% adjusted gross margin — but the gap between adjusted and GAAP is the cost of the Lima integration. In January 2024, Enovis acquired LimaCorporate S.p.A. for an enterprise value of €800 million (roughly $846 million at the time), adding a heavy debt load and a mountain of acquisition-related amortization to the income statement. The GAAP numbers reflect that reality. The adjusted numbers do not. You need to know which one you're looking at before you call the stock cheap.

Safety: C–. Total debt stands at $2.29 billion against only $12.6 million in cash, giving net debt of $1.27 billion and a debt-to-equity ratio of 86.8%. The current ratio of 1.99x and quick ratio of 1.00x are adequate — the company can meet its short-term obligations — but this is a highly leveraged profile for a growth-stage medtech firm. Free cash flow for the trailing twelve months is $63.7 million, up from a very low base (1,711% year-over-year growth, which is impressive but starts from essentially zero). Operating cash flow of $270.1 million is healthy; capital expenditure of $206.4 million is heavy, likely reflecting ongoing Lima integration spending. The balance sheet is not in distress, but it is not relaxed either.

Momentum: C+. The stock is up 22.2% over the past 120 days but down 8.7% over the last five days. It sits at $26.61, above the 50-day moving average ($24.65) and above the 200-day moving average ($25.43). The RSI at 48.3 is neutral, neither overbought nor oversold. The MACD is positive at 1.14, suggesting mild upward pressure. Technical structure is supportive but not compelling — this isn't a momentum story, and the five-day pullback suggests the post-earnings reaction was mixed, not enthusiastic.

What the Comparison Set Says

The core reason ENOV trades at a steep discount to Zimmer Biomet and Stryker is not a story problem. It's a capital-structure problem. Those peers operate with positive GAAP earnings, positive returns on capital, and dividend yields around 1%. ENOV pays no dividend, burns equity value on a GAAP basis, and carries debt that was largely raised to fund the Lima acquisition.

AInvest's aggregate signal labels the stock a Buy, with composite analysis and fundamental ratings both above 7 on a 10-point scale. That cross-check does not contradict the factor stack — it reflects the same adjusted-EPS improvement and margin trajectory that show up in the growth and profitability grades. But the AInvest signal doesn't penalize for debt the way a leveraged-balance-sheet investor would.

Wells Fargo maintains an Overweight rating on the name, citing a forward P/E of roughly 6x in its undervalued zone. That forward multiple is calculated against the $3.52–$3.73 adjusted EPS guidance, not GAAP. If you accept the adjusted number as the real earnings power, the valuation looks materially below peers. If you don't, the negative forward P/E tells you the market has reasons to be skeptical.

What to Watch

The Lima integration costs declined significantly year over year — strategic transaction costs fell from $13.5 million in Q2 2025 to $1.4 million in Q2 2026. That's the single most important trend in the factor stack. If those charges continue to fade, GAAP earnings should eventually catch up to adjusted earnings, and the discount that exists today will compress. The trajectory is improving, and that matters more than any single quarter.

The trigger that changes the rating is guidance expansion, not reaffirmation. A raise on the $425–$435 million adjusted EBITDA range would signal that the Lima integration has crossed from cost to contribution. Until then, the process says hold for the improvement path, not sell the idea entirely.

Portfolio Role

ENOV belongs in a turnaround sleeve, not a core growth allocation. The margin expansion trend is real, the debt is manageable (not optimal, but not crisis-level), and the adjusted earnings trajectory supports a patient position. But this is not a barbell anchor, and it is not a high-conviction compounder at these factor grades.

The stock makes sense if you believe the Lima integration is maturing faster than the GAAP numbers currently show. It loses appeal if revenue growth stalls below the 4–6% organic range or if macro pressure forces capex discipline that slows integration. The bar is not low — it's just not as low as the sub–1x sales multiple implies.

Every stock needs a named role. For ENOV, the role is optionality on medtech consolidation: you're paying for the upside of a balance sheet that cleans up as Lima amortization fades, with the downside cushioned by the valuation gap. That's a barbell position in itself — cheap enough to absorb a stumble, improving enough to reward patience. But it's not a stock you pile into because the P/S ratio looks small.